Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A

This Week:Our Year in Review series is in full swing, with 23 guest articles, interviews, panels and mini-reports published so far. You can find them all on this dedicated webpage.This week’s Bulletin will catch you up on some key headlines from the past few weeks, including: and lots more… The headline: Australia Recognises MDMA and Psilocybin as Medicines; Limited Rescheduling Decision Makes…

Source